Vivos Inc. reported a significant increase in revenue for the fiscal year ending December 31, 2025, generating $68,379 compared to $27,995 in 2024, marking a 144% increase. However, the company also experienced a net loss of $3,066,017, slightly higher than the previous year's loss of $2,910,448. The increase in revenue was primarily attributed to the sales of IsoPet® therapies and the licensing and certification of veterinary clinics, which accounted for approximately $27,000 of the total revenue. Despite the revenue growth, the cost of goods sold rose sharply to $128,134 from $30,979, contributing to a gross loss of $59,755.
Operational expenses also increased, totaling $3,105,292 in 2025, up from $2,601,400 in 2024. This rise was driven by higher professional fees, payroll expenses, and research and development costs as the company ramped up its product development efforts, particularly in India and the U.S. The company has been focusing on its IsoPet® division, which reported a remarkable 1,200% year-over-year increase in administered therapies, expanding its network to 17 certified clinics nationwide.
Strategically, Vivos Inc. has made significant organizational changes, including the appointment of Brad Allan Weeks as President and David J. Swanberg as Chief Operating Officer in September 2025. These appointments are aimed at enhancing operational efficiency and supporting the rapid expansion of the IsoPet® division. Additionally, the company established Vivos Scientific India LLP in September 2025, which will serve as its first international manufacturing center and facilitate clinical trials in India, furthering its goal of expanding its market presence.
Looking ahead, Vivos Inc. anticipates requiring approximately $9 million in additional capital over the next 36 months to fund FDA approval processes, clinical trials, and the establishment of regional clinics for IsoPet®. The company is actively pursuing financing options, including a Regulation A+ Offering to raise up to $75 million. Despite the challenges, Vivos Inc. remains optimistic about achieving breakeven status in its Animal Therapy Division by 2026, supported by ongoing profitability-focused initiatives and the anticipated growth in both human and veterinary applications of its Precision Radionuclide Therapy™ platform.
About VIVOS INC
Vivos Inc. develops precision radionuclide therapy devices, primarily RadioGel, for treating non-resectable tumors in humans and animals. Its core focus includes FDA-approved cancer treatments, veterinary oncology solutions under the IsoPet brand, and innovative isotope technologies. The company leverages strategic partnerships, proprietary patents, and clinical trials to deliver targeted, minimally invasive therapies with competitive advantages in safety, efficacy, and regulatory progress.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.